3/21
01:31 am
rna
Low
Report
3/13
06:18 am
rna
Avidity Biosciences (RNA) was upgraded by Wells Fargo & Company to "strong-buy".
Medium
Report
Avidity Biosciences (RNA) was upgraded by Wells Fargo & Company to "strong-buy".
3/11
09:00 am
rna
Avidity Biosciences (RNA) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $25.00 price target on the stock.
Medium
Report
Avidity Biosciences (RNA) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $25.00 price target on the stock.
2/23
08:00 am
rna
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Low
Report
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
2/18
05:00 pm
rna
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Low
Report
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
2/2
10:08 pm
rna
Avidity Biosciences Announces Expected Record Date for Spin-Off [Yahoo! Finance]
Low
Report
Avidity Biosciences Announces Expected Record Date for Spin-Off [Yahoo! Finance]
2/2
09:44 pm
rna
Avidity Biosciences Announces Expected Record Date for Spin-Off
Low
Report
Avidity Biosciences Announces Expected Record Date for Spin-Off
1/23
05:06 am
rna
Avidity Biosciences (NASDAQ:RNA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Avidity Biosciences (NASDAQ:RNA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/13
12:02 pm
rna
JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals [Yahoo! Finance]
Low
Report
JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals [Yahoo! Finance]
1/13
06:33 am
rna
SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody [Yahoo! Finance]
Low
Report
SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody [Yahoo! Finance]